葡萄糖协同转运蛋白2抑制剂防治心力衰竭的研究进展

心力衰竭是合并动脉粥样硬化性心血管疾病(ASCVD)和ASCVD高危因素2型糖尿病(T2DM)患者最常见的并发症之一。临床试验显示葡萄糖协同转运蛋白2抑制剂(SGLT2i)可有效预防心力衰竭住院的发生。新的证据表明SGLT2i治疗确诊的合并和不合并T2DM的心力衰竭患者明显获益,更多的循证医学依据正在积累中。虽然SGLT2i耐受性良好,但应对严重不良作用进行监测。本文主要介绍SGLT2i防治心力衰竭的获益、不良作用和可能机制。

Research progress of sodium-glucose co-transporter 2 inhibitors in prevention and treatment of heart failure

Heart failure is one of the most common complications in patients with type 2 diabetes mellitus (T2DM) with, or at risk for, atherosclerotic cardiovascular disease (ASCVD). Clinical trials indicated that sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated consistent reductions in hospitalization due to heart failure in this population. Emerging evidence also suggested that SGLT2i are beneficial to heart failure patients regardless of the presence of T2DM or not, and more evidence is accumulating. Although the inhibitors are well tolerated, clinical monitoring should be performed for serious adverse effects. This review summarizes the benefits, adverse effects, and proposed mechanisms of SGLT2i in prevention and treatment of heart failure.